SpicyIP

SEPTEMBER 11, 2023

Image from here In the previous months, I journeyed through the posts published in “ Junes ” and “ Julys ” of decades past on SpicyIP, tracking how some IP stories developed over the years. He wrote detailed posts on this topic later here and here. Upon an online search, I only found MHRD IP Chair websites.

IP 105

IP Reporting Plagiarism Government 105

LexBlog IP

DECEMBER 13, 2022

As for branding, trademark protection is not available for flower until cannabis is removed as a Schedule I drug. TINCTURES, EDIBLES AND TOPICALS. Topicals also have very low bioavailability, since they cannot penetrate the skin. Vaping is one of the most efficient ways to consume cannabis.

Technology 52

Technology Intellectual Property Trademark IP 52

LexBlog IP

MARCH 6, 2023

However, the court noted that products which are per se drug paraphernalia such as bongs, chillums, and roach clips would not have withstood its scrutiny. § 863 (d)(1)-(15) listing per se drug paraphernalia). at *2 ( citing 21 U.S.C. § The reasoning in Gene Pool Techs. The courts in Gene Pool Techs. and Lifted Ltd.,

Litigation 52

Litigation Patent Design Patent Patent Application 52

Fish & Richardson Trademark & Copyright Thoughts

DECEMBER 2, 2020

Cannabis [i] is a rapidly growing industry; in 2019, overall sales of cannabis products legal under state law were estimated to be worth $13.6 ii] While marijuana remains a Schedule I controlled substance under federal law, a majority of states have legalized consumption of certain cannabis products under certain conditions.

IP 52

IP Registration Trademark Branding 52

SpicyIP

DECEMBER 30, 2023

As in previous years, we have divided these developments into five categories: a) Top 10 IP Judgements/Orders (Topicality/Impact) b) Top 10 IP Judgements/Orders (Jurisprudence/Legal Lucidity) c) Top 10 IP Legislative and Policy Related Developments d) Other IP Developments; and e) Other Notable Developments. RDB and Co. Hari Shankar.

IP 124

IP Copyright Trademark Intellectual Property 124

Fish & Richardson Trademark & Copyright Thoughts

JANUARY 11, 2022

Biosimilar Drug. In 2021, regulatory agencies focused on three interrelated issues: (1) decreasing anti-competitive behavior in the biosimilars space, (2) lowering biologic drug prices, and (3) providing further guidance to clarify the regulatory pathway for biosimilars. Tackling Biologic Drug Pricing. BPCIA Litigation.

Litigation 52

Litigation Settlement Patent Marketing 52

Fish & Richardson Trademark & Copyright Thoughts

FEBRUARY 7, 2022

Here, the trial is scheduled to begin around the same time as our deadline to reach a final decision. Following a year in which only three post-grant petitions were filed against patents covering biologic drugs, 2021 saw 18 biologic IPR petitions and 5 biologic PGR petitions filed. The POP did not schedule an oral hearing.

Reporting 52

Reporting Art Invention Patent 52